32 | DNA (Deoxyribonucleic Acid)IBA
02/2024
-
07/2002 |
12 | Immunoconjugates (Immunoconjugate)IBA
02/2024
-
11/2015 |
9 | pyrrolo(2,1-c)(1,4)benzodiazepineIBA
07/2023
-
11/2016 |
9 | Cisplatin (Platino)FDA LinkGeneric
01/2020
-
03/2004 |
5 | ProdrugsIBA
10/2019
-
11/2004 |
5 | ErbB Receptors (EGF Receptor)IBA
06/2016
-
10/2004 |
4 | Biomarkers (Surrogate Marker)IBA
11/2021
-
04/2015 |
4 | 1,1'- ((propane- 1,3- diyl)dioxy)bis(7- methoxy- 2- methylidene- 1,2,3,10,11,11a- hexahydro- 5H- pyrrolo(2,1- c)(1,4)benzodiazepin- 5,11- dione)IBA
06/2011
-
09/2004 |
3 | Poly(ADP-ribose) Polymerase InhibitorsIBA
01/2022
-
04/2015 |
3 | Proteins (Proteins, Gene)FDA Link
03/2015
-
09/2004 |
3 | Gefitinib (Iressa)FDA Link
12/2013
-
10/2004 |
3 | Melphalan (Alkeran)FDA LinkGeneric
09/2012
-
07/2002 |
3 | Etoposide (VP 16)FDA LinkGeneric
11/2009
-
10/2004 |
2 | Peptides (Polypeptides)IBA
02/2024
-
01/2020 |
2 | Cytotoxins (Cytolysins)IBA
02/2024
-
11/2004 |
2 | loncastuximab tesirineIBA
01/2023
-
01/2018 |
2 | olaparibIBA
01/2022
-
02/2018 |
2 | vandetanib (ZD6474)IBA
01/2022
-
10/2019 |
2 | 1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA
11/2021
-
03/2015 |
2 | N- (2,3- dihydroxypropyl)- 1- ((2- fluoro- 4- iodophenyl)amino)isonicotinamideIBA
02/2018
-
12/2015 |
2 | A-factor (Streptomyces)IBA
10/2017
-
07/2010 |
2 | Trastuzumab (Herceptin)FDA Link
01/2017
-
11/2009 |
2 | GemcitabineFDA Link
12/2015
-
10/2010 |
2 | PoisonsIBA
12/2013
-
09/2004 |
2 | PlatinumIBA
09/2012
-
10/2010 |
2 | Drug CombinationsIBA
06/2011
-
07/2010 |
2 | Nylons (Nylon)IBA
05/2010
-
01/2007 |
2 | Mechlorethamine (Nitrogen Mustard)FDA Link
05/2007
-
11/2004 |
1 | N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA
02/2024 |
1 | IminesIBA
01/2023 |
1 | AZD 8931IBA
01/2023 |
1 | monomethyl auristatin EIBA
01/2022 |
1 | auristatinIBA
01/2022 |
1 | Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
01/2022 |
1 | Formaldehyde (Formol)FDA Link
11/2021 |
1 | ParaffinIBA
11/2021 |
1 | Chimeric Antigen ReceptorsIBA
10/2021 |
1 | SteroidsIBA
10/2021 |
1 | LigandsIBA
09/2021 |
1 | futuximabIBA
01/2020 |
1 | Cell Surface ReceptorsIBA
01/2020 |
1 | IntegrinsIBA
01/2020 |
1 | GlucuronidaseIBA
10/2019 |
1 | Histones (Histone)IBA
10/2018 |
1 | glutamate carboxypeptidaseIBA
10/2018 |
1 | MEDI3726IBA
10/2018 |
1 | AntigensIBA
10/2018 |
1 | Adenosine Diphosphate (ADP)IBA
02/2018 |
1 | Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
02/2018 |
1 | TH 302IBA
02/2018 |
1 | Adenosine Diphosphate Ribose (ADP-Ribose)IBA
02/2018 |
1 | CD19 AntigensIBA
01/2018 |
1 | Immunoglobulins (Immunoglobulin)IBA
01/2018 |
1 | Tubulin ModulatorsIBA
01/2018 |
1 | Membrane Glycoproteins (Membrane Glycoprotein)IBA
01/2018 |
1 | Interleukin-2 (IL2)IBA
10/2017 |
1 | ChromatinIBA
01/2017 |
1 | rovalpituzumab tesirineIBA
11/2016 |
1 | Cetuximab (Erbitux)FDA Link
06/2016 |
1 | Reactive Oxygen Species (Oxygen Radicals)IBA
06/2016 |
1 | Oxaliplatin (Eloxatin)FDA LinkGeneric
06/2016 |
1 | ElementsIBA
01/2016 |
1 | Transcription Factors (Transcription Factor)IBA
01/2016 |
1 | Ribonucleotide Reductases (Ribonucleotide Reductase)IBA
12/2015 |
1 | NucleosidesIBA
12/2015 |
1 | Caspase 3 (Caspase-3)IBA
12/2015 |